We carried out a randomised phase @ trial of patients aged @ years or older from @ hospitals , clinics , and academic medical centres in @ countries who had confirmed progressive disease within @ weeks after two or more ipilimumab doses and , if BRAF ( V@ ) mutant-positive , previous treatment with a BRAF or MEK inhibitor or both .